Avanos Medical (AVNS)
(Delayed Data from NYSE)
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth C Momentum D VGM
Zacks News
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
by Zacks Equity Research
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Medtronic (MDT) to Enhance AI Innovation With New Platform
by Zacks Equity Research
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Quest Diagnostics (DGX) Advances Transplant Testing Service
by Zacks Equity Research
These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
by Zacks Equity Research
Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Neogen (NEOG) Receives New Label Claims for Viroxide Super
by Zacks Equity Research
Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions
by Zacks Equity Research
Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal
by Zacks Equity Research
The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.
Is Avanos Medical (AVNS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage
by Zacks Equity Research
With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.
Merit Medical's (MMSI) New Launch to Boost its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
Shockwave Medical (SWAV) Launches New IVL Catheter in U.S.
by Zacks Equity Research
Shockwave Medical's (SWAV) latest U.S. launch is expected to serve a wider patient pool.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
by Zacks Equity Research
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.